Session: 77. Use of PK/PD to optimize existing antibiotics and antifungals Thursday, October 5, 2017: 12:30 PM Background. Multidrug-resistant A. baumannii, S. maltophilia, and B. cepacia have been identified as priority organisms of infectious diseases and as important causes of refractory pneumonia. These three pathogens require urgent attention for development of new therapeutic options. However, few if any novel antibacterial antibiotics against these organisms are available. In order to understand the impact of minocycline dose on plasma and tissue distribution, we conducted a detailed pharmacokinetic study in rabbits.
The data show that minocycline tissue exposures increased with increasing minocycline doses and minocycline plasma levels increased in a dose-proportional manner. Minocycline was highly distributed in tissues and body fluids including choroid, epithelial lining fluid, alveolar macrophages, vitreous and aqueous humor, and CSF.
Conclusion. These data suggest that administration of minocycline in rabbits should produce levels of drug that would be active against target organisms in plasma, tissues, and other body fluids. Background. Glycopeptide antibiotics, principally, vancomycin, have been the first armamentarium against MRSA. However, Staphylococcus aureus strains have now developed reduced susceptibility to common glycopeptides. (DAL) is a novel, 2 nd generation lipoglycopeptide antibiotic with reported activity against Gram-positive bacterial pathogens, including MRSA. The long lipophilic lateral chain in DAL's structure extends its half-life and promotes its anchoring to the cell membrane (vancomycin lacks this side chain). While a considerable amount of data is available on susceptibility testing for this agent, information regarding the potential for synergy with β-lactams with newer lipoglycopeptides, including dalbavancin, is lacking. Our objective was to evaluate the impact of DAL or vancomycin (VAN) in combination with ceftaroline (CPT) against MRSA.
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Methods. MRSA 494 was studied in six different regimens independently. All the experiments were performed in one-compartment PK/PD models in duplicate during 7 days. DAL 1,500 mg day one fCmax = 30.1 µg/mL, VAN 2 g q12hr fCmax = 36 µg/ mL, CPT 600 mg every 12 hours fCmax = 17.04 µg/mL, DAL 1,500 mg day 1 plus CPT 600 mg q12hr, VAN 2 g q12hr plus Ceftaroline 600 mg q12hr and Growth Control. Antibiotic carry over was accounted for by washing and centrifugation of the samples. Model samples were plated and counted using an automated colony counter and differences in log 10 CFU/mL between regimens was evaluated.
Results. Combination of DAL + CPT offered a significant reduction in log 10 CFU/ mL amounts (more than 5 log 10 CFU/mL and up to detection limits) in 24 hours compared with CPT alone. CPT alone demonstrated bactericidal activity with a reduction >3 log 10 CFU/mL by 32 hours although regrowth without resistance was observed after 72 hours. Mean CFU/mL for DAL models reached detection limits in 72 hours and no regrowth was detected after this time.
Conclusion. Combination of DAL+ ceftaroline offers encouraging results for MRSA strain 494. This combination therapy can potentially lead to optimizing patient outcomes and preserving dalbavancin therapy for serious MRSA infections through utilization of ideal combinations and dose exposures.
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